# Bovine Arterial Tissue

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/bovine-arterial-tissue
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 2 / 10
**Category:** Protein
**Also Known As:** Bovine vascular graft, Cattle arterial tissue, Decellularized bovine artery, Bovine carotid artery graft, BAT (Bovine Arterial Tissue), Xenogenic arterial graft, Bovine vascular scaffold, Processed bovine arterial matrix

## Overview

Bovine arterial tissue is a glandular extract derived from cattle arteries, composed primarily of collagen type I and III, elastin, and glycosaminoglycans that provide structural matrix components for vascular support. It is used clinically as a biological scaffold material and in glandular supplement protocols theorized to deliver organ-specific peptides and extracellular matrix proteins to support vascular tissue integrity.

## Health Benefits

• Vascular graft applications for hemodialysis access (moderate evidence from NCT03300024 trial with 100 patients)
• Tissue engineering scaffold for vascular reconstruction (preliminary evidence from in vitro studies)
• Structural support for damaged arteries in surgical applications (limited clinical evidence from 1974 study PMID: 4473842)
• Potential for reendothelialization when seeded with human cells (preliminary laboratory evidence only)
• No evidence exists for oral supplementation benefits - all research pertains to surgical implantation

## Mechanism of Action

Bovine arterial tissue supplies extracellular matrix proteins—primarily type I and III collagen and elastin—that serve as structural scaffolds promoting endothelial cell adhesion and smooth muscle cell proliferation via integrin-mediated signaling pathways, particularly through α2β1 and αvβ3 integrins. Glycosaminoglycans such as heparan sulfate within the matrix bind growth factors including FGF-2 and VEGF, potentiating their receptor activation and supporting neovascularization. Glandular extract proponents additionally propose that organ-specific oligopeptides may survive partial [digestion](/ingredients/condition/gut-health) and exert tissue-targeted trophic effects, though this mechanism lacks robust human pharmacokinetic validation.

## Clinical Summary

The strongest clinical evidence comes from NCT03300024, a randomized controlled trial enrolling 100 patients that evaluated bovine arterial tissue as a vascular graft for hemodialysis access, demonstrating moderate evidence of patency and biocompatibility outcomes. Preclinical in vitro studies have shown that decellularized bovine arterial scaffolds support endothelial re-seeding and mechanical compliance comparable to native vessel walls, though these findings have not yet been replicated in large human trials. Surgical case series provide limited evidence supporting use as a structural reinforcement material in arterial reconstruction, but controlled data on quantified clinical outcomes such as graft survival rates and complication incidence remain sparse. As an oral glandular supplement, no peer-reviewed human clinical trials have established efficacy, dosing parameters, or measurable biomarkers of effect.

## Nutritional Profile

Bovine arterial tissue is primarily composed of structural proteins, with protein content estimated at 60-70% dry weight. Key macronutrients include: Protein (60-70% dry weight), predominantly collagen (Types I and III, ~40-50% of total protein), elastin (~20-30% of total protein), and smooth muscle contractile proteins (actin, myosin, ~10-15% of total protein). Fat content is present as membrane phospholipids and residual lipids (~5-15% dry weight), including phosphatidylcholine and sphingomyelin. Carbohydrates are minimal (<5% dry weight), primarily as glycosaminoglycans (heparan sulfate, chondroitin sulfate, dermatan sulfate) and proteoglycans. Bioactive compounds include: elastin-derived peptides with potential vasoactive properties, collagen-derived peptides (hydroxyproline-rich sequences), and glycosaminoglycans with anticoagulant and structural roles. Micronutrient content is limited but includes calcium (~2-5 mg/g dry weight associated with arterial calcification in aged tissue), phosphorus (~1-3 mg/g dry weight), zinc (~0.1-0.3 mg/g dry weight as a cofactor in matrix metalloproteinases), and copper (~0.05-0.1 mg/g dry weight associated with lysyl oxidase crosslinking activity). Bioavailability notes: As a surgical/biomedical material rather than a dietary ingredient, nutritional bioavailability is not the primary consideration; collagen-derived peptides if digested yield hydroxyproline and glycine at high concentrations; glutaraldehyde fixation used in vascular graft processing significantly reduces digestibility and bioavailability of all components.

## Dosage & Preparation

No standardized dosage exists for bovine arterial tissue as a dietary supplement. Current clinical applications involve surgical implantation of tissue-engineered vascular grafts with dimensions determined by specific surgical needs rather than standardized concentrations. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

The primary safety concern with bovine arterial tissue products is the theoretical risk of prion transmission (bovine spongiform encephalopathy), making sourcing from certified BSE-free herds and countries with low BSE prevalence critically important. Immunogenic reactions to residual bovine proteins are possible, particularly in individuals with known beef or bovine collagen allergies, and may manifest as localized [inflammation](/ingredients/condition/inflammation) or systemic hypersensitivity. In surgical graft applications, risks include graft thrombosis, infection, and aneurysmal dilation, as documented in vascular surgery literature. As an oral supplement, interactions with anticoagulant medications such as warfarin are theoretically possible due to the heparan sulfate content, and safety in pregnancy and lactation has not been established, warranting avoidance in these populations.

## Scientific Research

The primary clinical evidence comes from a randomized controlled trial (NCT03300024) comparing bovine carotid artery biologic grafts with ePTFE for hemodialysis access in 100 patients. Historical clinical use dates to at least 1974 (PMID: 4473842) examining modified bovine arterial grafts. Multiple in vitro studies have demonstrated successful recellularization with human endothelial cells, but these remain experimental without widespread clinical application.

## Historical & Cultural Context

Bovine arterial tissue has no documented traditional medicine use. Its application is entirely modern, originating from 20th-century surgical innovation (documented from at least 1974) as a biomedical device for vascular reconstruction rather than a dietary supplement.

## Synergistic Combinations

Not applicable - bovine arterial tissue is a surgical biomaterial, not a dietary supplement

## Frequently Asked Questions

### What is bovine arterial tissue used for in supplements?

In glandular supplement formulations, bovine arterial tissue is included to deliver organ-specific proteins including collagen type I and III, elastin, and glycosaminoglycans theorized to support vascular tissue health. Proponents of the glandular therapy concept suggest that bioactive peptides derived from arterial tissue may exert trophic effects on human blood vessels, though human pharmacokinetic and efficacy data for oral use are currently lacking.

### Is bovine arterial tissue safe to take as a supplement?

Bovine arterial tissue carries a theoretical prion transmission risk, so products should be sourced exclusively from herds certified BSE-free in countries with negligible BSE risk, such as New Zealand or Australia. Individuals with bovine protein allergies should avoid it, and those taking anticoagulants like warfarin should consult a physician before use due to the potential heparan sulfate content influencing coagulation pathways.

### What evidence supports bovine arterial tissue as a vascular graft?

The NCT03300024 clinical trial, enrolling 100 patients, provided moderate-quality evidence supporting bovine arterial tissue grafts for hemodialysis vascular access, assessing patency rates and complication profiles. Additional support comes from in vitro tissue engineering studies demonstrating that decellularized bovine arterial scaffolds maintain mechanical compliance and support endothelial cell adhesion via integrin signaling, though large-scale randomized trials comparing it to synthetic grafts are still limited.

### What bioactive compounds are found in bovine arterial tissue?

Bovine arterial tissue contains type I and type III collagen as its primary structural proteins, along with elastin responsible for arterial recoil and compliance, and glycosaminoglycans including heparan sulfate and chondroitin sulfate that regulate growth factor binding. It also contains matrix proteins such as fibronectin and laminin that mediate cell adhesion through integrin receptors, and trace amounts of vascular smooth muscle cell-derived signaling peptides.

### How does bovine arterial tissue compare to synthetic vascular grafts?

Bovine arterial tissue grafts offer biological compatibility advantages over synthetic materials like ePTFE or Dacron, including a natural extracellular matrix architecture that promotes endothelialization and reduces thrombogenicity through heparan sulfate-mediated anticoagulant activity. However, synthetic grafts offer greater mechanical predictability and longer shelf life, and direct comparative randomized controlled trial data between bovine arterial grafts and modern synthetic options in hemodialysis access remain limited, making definitive superiority claims premature.

### Who is bovine arterial tissue supplementation most appropriate for?

Bovine arterial tissue is primarily used in clinical and surgical settings rather than oral supplementation, making it most appropriate for patients with compromised vascular function requiring hemodialysis access or arterial reconstruction. Those with chronic kidney disease requiring vascular grafts and patients with arterial damage from trauma or disease may benefit from this tissue-based approach. It is not typically recommended as a general dietary supplement for healthy individuals without specific vascular pathology.

### What is the current clinical evidence quality for bovine arterial tissue in vascular applications?

Clinical evidence for bovine arterial tissue is mixed, with a moderate-quality randomized controlled trial (NCT03300024) involving 100 hemodialysis patients showing promising results for vascular graft applications. However, most tissue engineering and reendothelialization applications remain at preliminary in vitro stages, and structural support evidence relies on limited historical data from a 1974 study. Overall, the strongest evidence exists for hemodialysis access grafting, while broader vascular reconstruction applications require further clinical validation.

### Are there contraindications or populations that should avoid bovine arterial tissue supplements?

Individuals with bovine protein allergies or sensitivities should avoid bovine arterial tissue products due to potential allergic reactions. Those with prion disease concerns or strict dietary restrictions against bovine-derived products may also wish to avoid this ingredient. Pregnant women and young children should consult healthcare providers before use, as clinical safety data in these populations is limited and applications are primarily surgical rather than supplemental.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*